Jazz Pharmaceuticals (JAZZ) Curent Deferred Tax Liability (2012 - 2015)

Jazz Pharmaceuticals' Curent Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $9.4 million for Q3 2015.

• On a quarterly basis, Curent Deferred Tax Liability rose 50.46% year-over-year to $9.4 million in Q3 2015; TTM through Sep 2015 was $9.4 million, a 50.46% increase from a year earlier, with the FY2014 full-year figure at $9.4 million, up 50.66% from the prior year.
• Curent Deferred Tax Liability held at $9.4 million in Q3 2015 per JAZZ's latest filing, from $9.4 million in the prior quarter.
• Across five years, Curent Deferred Tax Liability topped out at $9.4 million in Q2 2015 and bottomed at $259000.0 in Q1 2013.
• The 4-year median for Curent Deferred Tax Liability is $6.3 million (2013), against an average of $5.3 million.
• Across the five-year window, Curent Deferred Tax Liability soared 2316.6% in 2014 and soared 50.46% in 2015, its largest moves.
• Year by year, Curent Deferred Tax Liability stood at $275000.0 in 2012, then soared by 2176.0% to $6.3 million in 2013, then soared by 50.66% to $9.4 million in 2014, then declined by 0.14% to $9.4 million in 2015.
• Per Business Quant, the three latest JAZZ Curent Deferred Tax Liability figures stand at $9.4 million (Q3 2015), $9.4 million (Q2 2015), and $9.4 million (Q1 2015).